Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
NYSE MKT:ATNM
RESEARCH TOOLSreports
Actinium Pharmaceuticals (ATNM) Stock Price & Analysis
2,010 Followers
ATNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $9.86
Previous Close$7.7
Volume227.26K
Average Volume (3M)370.35K
Market Cap
$201.95M
Enterprise Value$154.77M
Total Cash (Recent Filing)$84.06M
Total Debt (Recent Filing)$9.49M
Price to Earnings (P/E)-4.5
Beta0.79
Next Earnings
Mar 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding29,783,451
10 Day Avg. Volume265,924
30 Day Avg. Volume370,352
Standard Deviation0.24
R-Squared0.00
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.91K
Enterprise Value/Gross Profit1.91K
Enterprise Value/Ebitda-5.16
Forecast
1Y Price Target
$30.50Price Target Upside292.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Actinium Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe initiation of a new clinical study for Iomab-ACT aims to improve outcomes and reduce toxicities of CAR-T therapy, potentially enhancing Actinium's value proposition in the competitive oncology market.
Regulatory ProgressActinium has received positive feedback from the FDA regarding the CMC package for Iomab-B, which has received a BLA number, indicating forward movement in its approval process.
Strategic InvestmentsActinium announces a strategic investment in a cyclotron-based method for high-purity Actinium-225 production, which could provide a separate revenue stream and secure a stable supply for its Actimab-A trials.
Bears Say
Company GuidanceAnalysts lower earnings per share estimates and price target after the company provides weak guidance for the future.
Financial PerformanceActinium reports significant net loss in its 4Q23 results, indicating potential financial instability.
Product Launch DelaysInvestor confidence may waver as the commercial launch of Iomab-B is postponed, pushing back potential revenue streams.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $4.00 and its highest was $9.86 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 315 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 15, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.23.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 29,783,451 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went up 7.656%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 254K.
---
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.50 (292.03% Upside)
$30.50 (292.03% Upside)
Blogger Sentiment
Bullish
ATNM Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-91.92%
Trailing 12-Months
Asset Growth
-13.40%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
ATNM Stock 12 Months Forecast
Average Price Target
$30.50
▲(292.03% Upside)
Technical Analysis
Best Analysts Covering ATNM
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-2.01%
reiterated a buy rating 4 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -2.01% per trade.
---